`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
` NDA 208411/S-001
`
`
`
`
`
`
`Richard E. Lowenthal, MS, MBA
`
`President, Pacific-Link Consulting
`
`
`Adapt Pharma Regulatory Representative
`
`
`
`
`
`
`Food and Drug Administration
`
`
` Silver Spring, MD 20993
`
`
`SUPPLEMENT APPROVAL
`
`
`
`
`
`
`
`
` Adapt Pharma Operations Limited
`
`
`
`c/o Pacific-Link Consulting
`
`8195 Run of the Knolls Court
`
`San Diego, CA 92127
`
`
`Attention:
`
`
`
`
`
`
`
`
`Dear Mr. Lowenthal:
`
`
`
`
`
`
`
`Please refer to your supplemental New Drug Application (sNDA) dated and received March 25,
`
`
`
`2016, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug,
`
`
`and Cosmetic Act (FDCA), for NARCAN (naloxone hydrochloride) Nasal Spray.
`
`
`
`
`
`
`This Prior Approval supplemental application proposes the addition of a 2 mg dosage strength
`
`
`
`
`for Narcan (naloxone hydrochloride) Nasal Spray.
`
`
`APPROVAL & LABELING
`
` We have completed our review of this supplemental application, as amended. It is approved,
`
`
`
`
` effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling
`
` text.
`
`WAIVER OF HIGHLIGHTS SECTION
`
`
`Please note that we have previously granted a waiver of the requirements of 21 CFR
`
`
`
`
`201.57(d)(8) regarding the length of Highlights of prescribing information.
`
`
`
`
`CONTENT OF LABELING
`
`
` As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`
`
`
`
`
` labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
` automated drug registration and listing system (eLIST), as described at
`
` http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`
`
`
`
`of labeling must be identical to the enclosed labeling text for the package insert, text for the
`patient package insert, and Instructions for Use, with the addition of any labeling changes in
`
`Reference ID: 4045900
`
`
`
`
`
`
`
`
`
` NDA 208411/S-001
`
` Page 2
`
`
` pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not
`
`
`
`included in the enclosed labeling.
`
`
`
`
`Information on submitting SPL files using eList may be found in the guidance for industry titled
`
`
`
`“SPL Standard for Content of Labeling Technical Qs and As at
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`CM072392.pdf
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
` Also within 14 days, amend all pending supplemental applications that include labeling changes
`
` for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`
` with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`
`
`
`
`
` changes approved in this supplemental application, as well as annual reportable changes and
`
`
`
` annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`
` up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`
`
`
`
`
`
`
` should provide appropriate annotations, including supplement number(s) and annual report
`date(s).
`
`
`CARTON AND IMMEDIATE CONTAINER LABELS
`
`
`
`
`Submit final printed carton and immediate container labels that are identical to the enclosed
`
`
`
`carton and immediate container labels, as soon as they are available, but no more than 30 days
`
`
`
`
`after they are printed. Please submit these labels electronically according to the guidance for
`
`
`
`industry Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical
`
`Product Applications and Related Submissions Using the eCTD Specifications (June 2008).
`
`Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on
`
`heavy-weight paper or similar material. For administrative purposes, designate this submission
`
`
`
`“Final Printed Carton and Container Labels for approved NDA 208411/S-001.” Approval
`
`
`
`of this submission by FDA is not required before the labeling is used.
`
`
`REQUIRED PEDIATRIC ASSESSMENTS
`
`Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new
`
`
`
`active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of
`
`
`
`administration are required to contain an assessment of the safety and effectiveness of the
`
`
`product for the claimed indication(s) in pediatric patients unless this requirement is waived,
`
`
`deferred, or inapplicable.
`
`
`This product is appropriately labeled for use in all relevant pediatric populations. Therefore, no
`additional pediatric studies are required at this time.
`
`
`
`
`
`
`
`
`Reference ID: 4045900
`
`
`
`
`
`
`
` NDA 208411/S-001
`
` Page 3
`
`
` PROMOTIONAL MATERIALS
`
`
`
`
`
`
`You may request advisory comments on proposed introductory advertising and promotional
`
`
`labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory
`comments, (2) the proposed materials in draft or mock-up form with annotated references, and
`
` (3) the package insert(s) to:
`
`
`
`
`
`OPDP Regulatory Project Manager
`
`Food and Drug Administration
`
`Center for Drug Evaluation and Research
`
`Office of Prescription Drug Promotion (OPDP)
`
`5901-B Ammendale Road
`
`Beltsville, MD 20705-1266
`
`
`
`
`Alternatively, you may submit a request for advisory comments electronically in eCTD format.
`For more information about submitting promotional materials in eCTD format, see the draft
`
`Guidance for Industry (available at:
`http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U
`CM443702.pdf ).
`
`
`
`You must submit final promotional materials and package insert(s), accompanied by a Form
`
`
`FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form
`
`
`
`
`
`FDA 2253 is available at
`
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf.
`Information and Instructions for completing the form can be found at
`
`
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For
`
`more information about submission of promotional materials to the Office of Prescription Drug
`
`
`
`Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.
`
`
`REPORTING REQUIREMENTS
`
`
`
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`(21 CFR 314.80 and 314.81).
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 4045900
`
`
`
` NDA 208411/S-001
`
` Page 4
`
`
`
` If you have any questions, call Diana L. Walker, PhD, Regulatory Project Manager, at (301) 796
` 4029.
`
`
`
`
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`Sharon Hertz, MD
`
`Director
`
`Division of Anesthesia, Analgesia, and
`
`
`Addiction Products
`
`Office of Drug Evaluation II
`
`Center for Drug Evaluation and Research
`
`
`
`
`
`
`
`
`
`
`
`ENCLOSURES:
`
`
`Content of Labeling
`
`
`Carton and Container Labeling
`
`
`Reference ID: 4045900
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`SHARON H HERTZ
`01/24/2017
`
`Reference ID: 4045900
`
`(
`
`
`
`